Our Synthetic Vaccine Particles (SVP™) technology is a highly flexible platform that is capable of incorporating a wide range of antigens and immunomodulators, allowing for the development of products that either induce antigen-specific tolerance or activate the immune system.
Selecta Bioscience’s primary focus is on developing and commercializing differentiated therapies that are designed to modulate the immune system to effectively and safely treat rare diseases by mitigating the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Tolerance-inducing SVP products also have potential applications in the treatment of allergies and autoimmune diseases. SVP products that stimulate the immune system can potentially prevent or treat cancer, infections and other serious diseases.
SVP are designed to remain intact after injection into the body and accumulate selectively in lymphoid organs, which include lymph nodes and the spleen, where significant immune responses are coordinated.
Depending on the type of immunomodulator encapsulated in the SVP, our technology is capable of either inducing a
- tolerogenic response, for example to a biologic drug to mitigate the formation of anti-drug antibodies (ADAs) or
- potent antigen-specific stimulatory response, such as an antibody response to a microbial antigen or a cytolytic T cell response to a tumor antigen.
Potential components of SVP Products